Market capitalization | $575.65m |
Enterprise Value | $556.40m |
P/E (TTM) P/E ratio | 58.51 |
EV/FCF (TTM) EV/FCF | 43.64 |
EV/Sales (TTM) EV/Sales | 7.95 |
P/S ratio (TTM) P/S ratio | 8.22 |
P/B ratio (TTM) P/B ratio | 3.15 |
Dividend yield | 0.84% |
Last dividend (FY24) | $0.24 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Simulations Plus, Inc. forecast:
7 Analysts have issued a Simulations Plus, Inc. forecast:
Aug '24 |
+/-
%
|
||
Revenue | 70 70 |
18%
18%
|
|
Gross Profit | 43 43 |
10%
10%
|
|
EBITDA | 12 12 |
9%
9%
|
EBIT (Operating Income) EBIT | 6.13 6.13 |
33%
33%
|
Net Profit | 9.95 9.95 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Head office | United States |
CEO | Shawn O'Connor |
Employees | 247 |
Founded | 1996 |
Website | www.simulations-plus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.